Wall Street analysts predict that Dova Pharmaceuticals Inc (NASDAQ:DOVA) will report earnings of ($0.65) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Dova Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.76) and the highest estimate coming in at ($0.59). Dova Pharmaceuticals posted earnings per share of ($0.69) in the same quarter last year, which would indicate a positive year over year growth rate of 5.8%. The firm is scheduled to issue its next quarterly earnings report on Thursday, November 14th.

On average, analysts expect that Dova Pharmaceuticals will report full year earnings of ($2.45) per share for the current year, with EPS estimates ranging from ($2.73) to ($2.23). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.77) per share, with EPS estimates ranging from ($2.82) to ($0.57). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Dova Pharmaceuticals.

Several equities analysts recently weighed in on the stock. ValuEngine lowered shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. BidaskClub lowered shares of Dova Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 6th. Wedbush lowered shares of Dova Pharmaceuticals from an “outperform” rating to a “neutral” rating and increased their price target for the company from $24.00 to $29.00 in a research report on Friday, October 4th. LADENBURG THALM/SH SH lowered shares of Dova Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $32.00 to $29.00 in a research report on Thursday, October 3rd. Finally, Oppenheimer assumed coverage on shares of Dova Pharmaceuticals in a research report on Thursday, August 29th. They set an “outperform” rating and a $30.00 price target for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $26.42.

In other Dova Pharmaceuticals news, VP Kevin Laliberte sold 3,100 shares of the company’s stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $20.00, for a total transaction of $62,000.00. Also, CEO David Zaccardelli sold 5,275 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $27.90, for a total transaction of $147,172.50. Over the last ninety days, insiders have sold 14,458 shares of company stock worth $379,497. Insiders own 60.30% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. lifted its holdings in Dova Pharmaceuticals by 231.5% during the third quarter. Meeder Asset Management Inc. now owns 988 shares of the company’s stock valued at $27,000 after purchasing an additional 690 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Dova Pharmaceuticals by 9,280.0% in the third quarter. Tower Research Capital LLC TRC now owns 1,876 shares of the company’s stock worth $52,000 after buying an additional 1,856 shares in the last quarter. Quantamental Technologies LLC lifted its holdings in shares of Dova Pharmaceuticals by 1,100.0% in the second quarter. Quantamental Technologies LLC now owns 2,400 shares of the company’s stock worth $34,000 after buying an additional 2,200 shares in the last quarter. Capital Investment Advisory Services LLC lifted its holdings in shares of Dova Pharmaceuticals by 222.2% in the second quarter. Capital Investment Advisory Services LLC now owns 2,900 shares of the company’s stock worth $45,000 after buying an additional 2,000 shares in the last quarter. Finally, Doyle Wealth Management purchased a new stake in shares of Dova Pharmaceuticals in the second quarter worth about $49,000. 33.03% of the stock is currently owned by institutional investors and hedge funds.

DOVA opened at $28.04 on Friday. The firm has a 50-day moving average of $26.72 and a 200 day moving average of $16.46. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.37 and a current ratio of 5.64. Dova Pharmaceuticals has a fifty-two week low of $5.62 and a fifty-two week high of $28.54.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Further Reading: What are high-yield dividend stocks?

Get a free copy of the Zacks research report on Dova Pharmaceuticals (DOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.